BIOCRAFT GENERIC CEPHALEXIN ANTI-DUMPING SUIT V. LYPHOMED: ITC RULES
Executive Summary
BIOCRAFT GENERIC CEPHALEXIN ANTI-DUMPING SUIT V. LYPHOMED: ITC RULES that there is evidence of material injury to the domestic cephalexin industry from the import of cephalexin capsules to the U.S. by a four-to-two vote on Dec. 7. The ruling by the International Trade Commission's six commissioners will kick off a full investigation by the Commerce Department, which has been awaiting the ITC preliminary decision. The ITC commissioners made their finding after reviewing a report drawn up by the ITC investigative staff on Biocraft's allegations of material injury resulting from the export of generic cephalexin to the U.S. by the Canadian joint venture LyphoMed/Novopharm ("The Pink Sheet" Dec. 5, p. 13). The report and the conclusions of the Commissioners are slated to be submitted to the Department of Commerce on Dec. 12, according to an ITC staffer. In a Nov. 16 Federal Register notice announcing that it was conducting an investigation of Biocraft's allegations against LyphoMed, the Commerce Department noted that continuation of its investigation is contigent upon ITC's determination of material injury. Commerce said it expects to make a "preliminary determination on or before April 5, 1989." According to ITC, a hearing will be held by the Commission should Commerce rule in favor of Biocraft. ITC initiated its preliminary investigation in response to an Oct. 27 petition from Biocraft. The petition claims that Canadian generic cephalexin capsule exporters have been "dumping" cephalexin on the U.S. market at "less than fair value" in order take customers away from domestic generic manufacturers. The filing also claims the "dumping" has resulted in a loss of profits for Biocraft because it has had to compete on price with Lyphomed ("The Pink Sheet" Nov. 14, T&G-6)
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth